Physician profile
Amy Tan
NPI 1932542149
$7,112.18
in general payments reported to CMS, 2019-2025
31 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $423 · 2022: $765 · 2023: $2,227 · 2024: $1,608 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,447.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,677.85 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Qol Medical, LLC | $1,450.33 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $563.63 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $458.36 | 2022-2025 | Ibsrela |
| Pfizer INC. | $330.86 | 2023-2025 | |
| Celgene Corporation | $311.70 | 2022-2024 | Zeposia |
| Novo Nordisk INC | $284.98 | 2019-2025 | Wegovy |
| Janssen Biotech, INC. | $274.35 | 2023-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.96 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $237.84 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $201.22 | 2020-2024 | Linzess |
| Redhill Biopharma INC. | $148.33 | 2020-2023 | Talicia |
| Phathom Pharmaceuticals, INC. | $129.74 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $128.09 | 2019-2023 | Rebyota |
| Lilly USA, LLC | $110.72 | 2024-2025 | Omvoh |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $98.22 | 2020-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $73.59 | 2022-2024 | Dupixent |
| Evoke Pharma, INC. | $55.11 | 2023-2024 | Gimoti |
| Ipsen Biopharmaceuticals, INC | $51.02 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $49.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $36.44 | 2019-2020 | |
| Concordia Pharmaceuticals INC. | $24.09 | 2019 | |
| Olympus America INC. | $21.68 | 2025 | Evis Exera III Video System Center |
| W. L. Gore & Associates, INC. | $19.40 | 2023 | Gore Cardioform Septal Occluder |
| Perspectum Diagnostics LTD | $15.65 | 2023 | Livermultiscan |
| Mauna Kea Technologies, INC. | $15.59 | 2023 | |
| Shionogi INC | $15.42 | 2019 | |
| Allergan, INC. | $14.90 | 2020 | |
| Intra-Sana Laboratories | $13.78 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Capsovision, INC. | $13.15 | 2023 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.